Spleen Tyrosine Kinase Confers Paclitaxel Resistance in Ovarian Cancer
- PMID: 26175410
- DOI: 10.1016/j.ccell.2015.06.008
Spleen Tyrosine Kinase Confers Paclitaxel Resistance in Ovarian Cancer
Abstract
Adaptive chemoresistance and consequent tumor recurrence present major obstacles to the improvement of the prognosis and quality-of-life of patients with advanced-stage ovarian cancer. In this issue of Cancer Cell, Yu and colleagues describe the critical role of spleen tyrosine kinase (SYK) in paclitaxel resistance by modulating the stability of microtubules.
Copyright © 2015 Elsevier Inc. All rights reserved.
Comment on
-
Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules.Cancer Cell. 2015 Jul 13;28(1):82-96. doi: 10.1016/j.ccell.2015.05.009. Epub 2015 Jun 18. Cancer Cell. 2015. PMID: 26096845 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
